Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) announced that results from the pivotal Phase 3 trial of Azstarys™ (serdexmethylphenidate chloride and dexmethylphenidate hydrochloride capsules) in Chinese children aged 6–12 years with attention‑deficit/hyperactivity disorder (ADHD) have been published in CNS Drugs. The study met its primary endpoint and the prespecified criterion for bridging efficacy consistency, with a favorable safety and tolerability profile – supporting the product’s commercial rollout in China, where exclusive commercialization is led by Qilu Pharmaceutical with launch expected before the end of 2026.
Regulatory & Publication Milestone
| Item | Detail |
|---|---|
| Company | Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) |
| Product | Azstarys™ (AK0901) – serdexmethylphenidate chloride / dexmethylphenidate HCl capsules |
| Publication | CNS Drugs – DOI: 10.1007/s40263‑026‑01341‑5 |
| Study Design | Randomized, double‑blind, placebo‑controlled Phase 3; 8 clinical sites across China |
| Population | Chinese children aged 6–12 years with ADHD |
| Key Results | Primary endpoint met; bridging efficacy consistency criterion met; favorable safety/tolerability |
| US Approval | FDA – March 2021 (ADHD, patients ≥6 years) |
| China Approval | NMPA – December 2025 (ADHD, patients ≥6 years) |
| Commercialization | Qilu Pharmaceutical – exclusive, mainland China; launch expected before end‑2026 |
Clinical Evidence – Pivotal Phase 3 Trial
- Leadership: Co‑led by Professor Yi Zheng (Beijing Anding Hospital, Capital Medical University) and Professor Jing Liu (Peking University Sixth Hospital).
- Efficacy: Azstarys™ significantly improved core ADHD symptoms versus placebo, with improvements observed across multiple secondary endpoints.
- Safety: Most treatment‑emergent adverse events were mild to moderate and transient; no serious drug‑related adverse events were reported.
- Significance: The findings provide clinical evidence supporting the use of Azstarys™ in Chinese children with ADHD, including the bridging efficacy consistency required for the population.
Drug Profile & Mechanism
- Formulation Innovation: The world’s first and only formulation combining immediate‑release dexmethylphenidate (d‑MPH) with the prodrug serdexmethylphenidate (SDX).
- Dual‑Release Benefit: Designed to deliver both rapid onset and sustained symptom control across the day – addressing a key limitation of single‑release stimulants.
- Approved Indication: Treatment of ADHD in patients aged 6 years and older in both the US and China.
- Nomenclature: Azstarys™ is the US‑approved trade name for AK0901.
Disease Background & Unmet Need
- ADHD is a common chronic neurodevelopmental disorder beginning in childhood and potentially persisting into adulthood, characterized by developmentally inappropriate inattention and/or hyperactivity–impulsivity.
- China Prevalence: Approximately 6.4 % among children and adolescents, with an estimated patient population exceeding 23 million.
- Unmet Need: ADHD impairs learning and multiple areas of functioning; treatment options – particularly innovative therapies balancing efficacy and safety – remain limited in China.
Market Impact & Outlook
- Commercial Launch Imminent: With NMPA approval in hand (December 2025) and Qilu Pharmaceutical leading exclusive commercialization, launch before end‑2026 would make Azstarys™ a new treatment option for children and adults with ADHD in China.
- Clinical Impact Potential: The dual‑release profile has the potential to improve patients’ learning, social and family functioning and contribute to advancing ADHD care standards in China.
- Pipeline Context: Azstarys™ is one of three lead assets at ArkBio, alongside ziresovir (AK0529) – the first direct‑acting antiviral for RSV with positive Phase 3 results – and AK3280, a potentially best‑in‑class anti‑fibrotic for idiopathic pulmonary fibrosis now in Phase 3.
- Strategic Network: ArkBio (founded 2014, commercial‑stage, respiratory & pediatric focus) has partnerships with Roche, Genentech, Qilu Pharmaceutical, and leading institutions including The Scripps Research Institute and the Institute of Microbiology, Chinese Academy of Sciences.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercial launch timing, market adoption, and clinical expectations for Azstarys™, as well as development timelines for ArkBio’s pipeline assets. Actual results may differ materially due to risks including commercialization execution, market access and reimbursement dynamics, clinical outcomes, and competitive pressures in the ADHD therapeutic market.-Fineline Info & Tech
